A key evolution in cell and gene therapy is the significant effort to target tissues beyond the liver, such as the lungs, kidneys, pancreas, and CNS. While a major technical and clinical challenge, this expansion is critical for moving beyond traditional ex vivo therapies and treating a wider range of diseases.

To overcome the historical issue of oncolytic viruses being sequestered by the liver, Accession re-engineers a human virus so it cannot infect any human cells. Only after this safety step is it re-targeted to infect only cancer cells, ensuring precise delivery and avoiding systemic side effects.

Early in treatment, tumors are "target-rich" with high PSMA expression, creating an ideal window for radioligand therapy. Citing data from the VISION trial, new clinical trials are being designed to accelerate dosing and intensity upfront to maximize impact, then de-escalate as the target diminishes.

The intravenous amivantamab regimen has faced adoption challenges due to practical burdens on patients and clinics, including long infusion times, infusion reactions, and scheduling difficulties. The shift to a subcutaneous formulation is a critical step to overcome these non-clinical barriers.

A fundamental conflict exists between optimal clinical practice and rigid trial design criteria. As seen with Replimune's RP1, injecting all tumors—the logical therapeutic approach—can leave no untreated lesions to measure systemic effect by RESIST criteria, leading the FDA to statistically disqualify a majority of responders.

Companies like VIR are making progress with masked T-cell engagers that limit systemic toxicity like cytokine release syndrome (CRS). This approach, which concentrates efficacy at the tumor site, could be the key to unlocking the broad potential of T-cell engagers beyond hematologic malignancies into the much larger solid tumor market.

Medical oncologists are trained to treat continuously to eliminate micrometastatic disease. Radioligand therapy challenges this dogma, as its effectiveness is tied to target volume. As tumors shrink, the therapy becomes less potent against the cancer and relatively more toxic to healthy organs, requiring a mental shift to an adaptive, physics-based model.

Historically, intratumoral therapy was limited by the physical difficulty of reaching tumors. The rise of a new discipline, Interventional Oncology, has largely solved this access problem. The critical bottleneck is now the lack of drugs specifically designed and optimized for local delivery and sustained retention within the tumor.

Integrating next-gen SCLC treatments like T-cell engagers requires more than education; it demands a physical and operational overhaul. Community practices must build infrastructure for 24-hour observation and establish proactive partnerships with specialists like ophthalmologists to manage novel toxicities.